Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Alcon's recent upgrades and promising opportunities, including the BELKIN Vision acquisition, expanding glaucoma treatment ...
Wells Fargo analyst Larry Biegelsen maintains Alcon (NYSE:ALC) with a Overweight and raises the price target from $89 to $94.
Oppenheimer analyst Steven Lichtman upgrades Alcon (NYSE:ALC) from Perform to Outperform and announces $103 price target.
Mizuho analyst Anthony Petrone maintains Alcon (NYSE:ALC) with a Buy and raises the price target from $100 to $105.
Baird analyst Jeff Johnson maintains Alcon (NYSE:ALC) with a Outperform and raises the price target from $95 to $104.
Stifel analyst Thomas Stephan maintains Alcon (NYSE:ALC) with a Buy and raises the price target from $95 to $100.
Needham analyst David Saxon maintains Alcon (NYSE:ALC) with a Buy and raises the price target from $98 to $101.
